Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

Updated on: October 03,2025 0

Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

Updated on:October 03,2025 0

Clinical study deepens understanding of mesothelioma, opens the door to potential treatment options

Updated on: October 03,2025 0

Clinical study deepens understanding of mesothelioma, opens the door to potential treatment options

Updated on:October 03,2025 0

Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC

Updated on: October 03,2025 0

Hypofractionated radiotherapy with chemotherapy offers comparable survival, lower toxicity in LS-SCLC

Updated on:October 03,2025 0

New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer

Updated on: October 03,2025 0

New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer

Updated on:October 03,2025 0

Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

Updated on: October 03,2025 0

Ivonescimab + chemotherapy improves progression-free survival in patients with EGFR+ NSCLC

Updated on:October 03,2025 0

Inhibiting an astrocytic 'brake' that blocks spinal cord repair could pave path to neuronal regeneration

Updated on: October 02,2025 0

Inhibiting an astrocytic 'brake' that blocks spinal cord repair could pave path to neuronal regeneration

Updated on:October 02,2025 0

Scientists identify novel therapeutic target for ovarian cancer

Updated on: October 02,2025 0

Scientists identify novel therapeutic target for ovarian cancer

Updated on:October 02,2025 0

Misconceptions keep some cancer patient populations from benefiting from hormone therapy, survey reveals

Updated on: October 02,2025 0

Misconceptions keep some cancer patient populations from benefiting from hormone therapy, survey reveals

Updated on:October 02,2025 0

Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC, trial shows

Updated on: October 02,2025 0

Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC, trial shows

Updated on:October 02,2025 0

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Updated on: October 02,2025 0

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

Updated on:October 02,2025 0